IRIS Accounts Production v25.1.4.42 10613047 Board of Directors 1.1.24 31.12.24 31.12.24 Medium entities wellness products true false true true false false false true false These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. Ordinary A 0.01000 Ordinary B 0.01000 Ordinary C 0.01000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh106130472023-12-31106130472024-12-31106130472024-01-012024-12-31106130472022-12-31106130472023-01-012023-12-31106130472023-12-3110613047ns15:EnglandWales2024-01-012024-12-3110613047ns14:PoundSterling2024-01-012024-12-3110613047ns10:Director12024-01-012024-12-3110613047ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3110613047ns10:MediumEntities2024-01-012024-12-3110613047ns10:Audited2024-01-012024-12-3110613047ns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-01-012024-12-3110613047ns10:Medium-sizedCompaniesRegimeForAccounts2024-01-012024-12-3110613047ns10:FullAccounts2024-01-012024-12-311061304712024-01-012024-12-3110613047ns10:OrdinaryShareClass12024-01-012024-12-3110613047ns10:OrdinaryShareClass22024-01-012024-12-3110613047ns10:OrdinaryShareClass32024-01-012024-12-3110613047ns10:Director22024-01-012024-12-3110613047ns10:Director32024-01-012024-12-3110613047ns10:Director42024-01-012024-12-3110613047ns10:RegisteredOffice2024-01-012024-12-311061304712024-01-012024-12-311061304712023-01-012023-12-3110613047ns5:CurrentFinancialInstruments2024-12-3110613047ns5:CurrentFinancialInstruments2023-12-3110613047ns5:Non-currentFinancialInstruments2024-12-3110613047ns5:Non-currentFinancialInstruments2023-12-3110613047ns5:ShareCapital2024-12-3110613047ns5:ShareCapital2023-12-3110613047ns5:SharePremium2024-12-3110613047ns5:SharePremium2023-12-3110613047ns5:FurtherSpecificReserve1ComponentTotalEquity2024-12-3110613047ns5:FurtherSpecificReserve1ComponentTotalEquity2023-12-3110613047ns5:RetainedEarningsAccumulatedLosses2024-12-3110613047ns5:RetainedEarningsAccumulatedLosses2023-12-3110613047ns5:ShareCapital2022-12-3110613047ns5:RetainedEarningsAccumulatedLosses2022-12-3110613047ns5:SharePremium2022-12-3110613047ns5:FurtherSpecificReserve1ComponentTotalEquity2022-12-3110613047ns5:RetainedEarningsAccumulatedLosses2023-01-012023-12-3110613047ns5:FurtherSpecificReserve1ComponentTotalEquity2023-01-012023-12-3110613047ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-3110613047ns5:FurtherSpecificReserve1ComponentTotalEquity2024-01-012024-12-3110613047ns5:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3110613047ns15:UnitedKingdom2024-01-012024-12-3110613047ns15:UnitedKingdom2023-01-012023-12-3110613047ns15:Europe2024-01-012024-12-3110613047ns15:Europe2023-01-012023-12-3110613047ns15:UnitedStates2024-01-012024-12-3110613047ns15:UnitedStates2023-01-012023-12-3110613047ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2024-01-012024-12-3110613047ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2023-01-012023-12-3110613047ns10:HighestPaidDirector2024-01-012024-12-3110613047ns10:HighestPaidDirector2023-01-012023-12-3110613047ns5:PlantEquipmentOtherAssetsUnderOperatingLeases2024-01-012024-12-3110613047ns5:PlantEquipmentOtherAssetsUnderOperatingLeases2023-01-012023-12-3110613047ns5:OwnedAssets2024-01-012024-12-3110613047ns5:OwnedAssets2023-01-012023-12-3110613047ns5:LeasedAssets2024-01-012024-12-3110613047ns5:LeasedAssets2023-01-012023-12-3110613047ns5:PatentsTrademarksLicencesConcessionsSimilar2024-01-012024-12-3110613047ns5:PatentsTrademarksLicencesConcessionsSimilar2023-01-012023-12-3110613047ns5:ComputerSoftware2024-01-012024-12-3110613047ns5:ComputerSoftware2023-01-012023-12-3110613047ns5:HirePurchaseContracts2024-01-012024-12-3110613047ns5:HirePurchaseContracts2023-01-012023-12-3110613047ns5:PatentsTrademarksLicencesConcessionsSimilar2023-12-3110613047ns5:ComputerSoftware2023-12-3110613047ns5:PatentsTrademarksLicencesConcessionsSimilar2024-12-3110613047ns5:ComputerSoftware2024-12-3110613047ns5:PatentsTrademarksLicencesConcessionsSimilar2023-12-3110613047ns5:ComputerSoftware2023-12-3110613047ns5:LandBuildingsns5:ShortLeaseholdAssets2023-12-3110613047ns5:FurnitureFittings2023-12-3110613047ns5:MotorVehicles2023-12-3110613047ns5:ComputerEquipment2023-12-3110613047ns5:LandBuildingsns5:ShortLeaseholdAssets2024-01-012024-12-3110613047ns5:FurnitureFittings2024-01-012024-12-3110613047ns5:MotorVehicles2024-01-012024-12-3110613047ns5:ComputerEquipment2024-01-012024-12-3110613047ns5:LandBuildingsns5:ShortLeaseholdAssets2024-12-3110613047ns5:FurnitureFittings2024-12-3110613047ns5:MotorVehicles2024-12-3110613047ns5:ComputerEquipment2024-12-3110613047ns5:LandBuildingsns5:ShortLeaseholdAssets2023-12-3110613047ns5:FurnitureFittings2023-12-3110613047ns5:MotorVehicles2023-12-3110613047ns5:ComputerEquipment2023-12-3110613047ns5:MotorVehiclesns5:LeasedAssetsHeldAsLessee2023-12-3110613047ns5:MotorVehiclesns5:LeasedAssetsHeldAsLessee2024-01-012024-12-3110613047ns5:MotorVehiclesns5:LeasedAssetsHeldAsLessee2024-12-3110613047ns5:MotorVehiclesns5:LeasedAssetsHeldAsLessee2023-12-3110613047ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3110613047ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3110613047ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2024-12-3110613047ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2023-12-3110613047ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2024-12-3110613047ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2023-12-3110613047ns5:HirePurchaseContracts2024-12-3110613047ns5:HirePurchaseContracts2023-12-3110613047ns5:WithinOneYear2024-12-3110613047ns5:WithinOneYear2023-12-3110613047ns5:BetweenOneFiveYears2024-12-3110613047ns5:BetweenOneFiveYears2023-12-3110613047ns5:AllPeriods2024-12-3110613047ns5:AllPeriods2023-12-3110613047ns5:DeferredTaxation2023-12-3110613047ns5:DeferredTaxation2024-01-012024-12-3110613047ns5:DeferredTaxation2024-12-3110613047ns10:OrdinaryShareClass12024-12-3110613047ns10:OrdinaryShareClass22024-12-3110613047ns10:OrdinaryShareClass32024-12-3110613047ns5:RetainedEarningsAccumulatedLosses2023-12-3110613047ns5:SharePremium2023-12-3110613047ns5:FurtherSpecificReserve1ComponentTotalEquity2023-12-3110613047ns5:SharePremium2024-01-012024-12-31106130471ns10:Director12023-12-31106130471ns10:Director12022-12-31106130471ns10:Director12024-01-012024-12-31106130471ns10:Director12023-01-012023-12-31106130471ns10:Director12024-12-31106130471ns10:Director12023-12-31
REGISTERED NUMBER: 10613047 (England and Wales)












LYMA LIFE LIMITED

STRATEGIC REPORT, REPORT OF THE DIRECTORS AND

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024






LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024




Page

Company Information 1

Strategic Report 2

Report of the Directors 3

Report of the Independent Auditors 5

Income Statement 9

Other Comprehensive Income 10

Balance Sheet 11

Statement of Changes in Equity 12

Cash Flow Statement 13

Notes to the Cash Flow Statement 14

Notes to the Financial Statements 15


LYMA LIFE LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2024







DIRECTORS: Mrs Sarah Jane Crook
Mrs Lucy Sarah Goff
Mrs Sian Eleri Westerman
Mr Andrew Daniel Wolfson





REGISTERED OFFICE: Edison House
223-231 Old Marylebone Road
London
NW1 5QT





REGISTERED NUMBER: 10613047 (England and Wales)





AUDITORS: Fruition Advisory LLP
29 Wood Street
Stratford-upon-Avon
CV37 6JG

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024

The directors present their strategic report for the year ended 31 December 2024.

PRINCIPAL ACTIVITY
The principal activity of the company is the supply and development of health and beauty solutions

REVIEW OF BUSINESS
Turnover for LYMA Life in the 12 months to 31 Dec 2024 fell by 9% with the company recording operating profit of £6,556 after exceptional items of £347,382.

2024 was a year of planned investment and strategic focus on long-term growth, particularly in the U.S., our largest market. Significant resources were directed toward building the team, strengthening the product pipeline, and advancing the regulatory process for FDA clearance of the LYMA Laser PRO. Clearance took longer than anticipated, which delayed the originally planned U.S. launch in the second half of 2024 and contributed to a temporary slowdown in sales.

The U.S. launch of the Laser PRO was successfully executed in Q2 2025, and early results have been encouraging, with initial sales exceeding forecasts despite challenging global economic conditions.

With 2024 serving as a year of investment and recalibration for international expansion, we believe LYMA Life is now well positioned to capitalise on global opportunities. Supported by strong trading, product innovation, and continued growth in 2025, we remain confident in our strategy and financial strength to deliver sustainable success.

PRINCIPAL RISKS AND UNCERTAINTIES
The directors recognise areas of risk to the business. They believe that the principal areas of risk relate to the economic outlook across the market. Customers, Suppliers and employees are all impacted by inflation and interest rates rises. The company is also exposed to foreign exchange risk with a proportion of sales from territories outside the UK, this is somewhat mitigate by supplier payments in equivalent territories.

The directors are confident that the company is well prepared to deal with the financial risk exposure.

KEY PERFORMANCE INDICATORS - FINANCIAL
The directors monitor a range of key performance indicators on a regular basis to evaluate both the financial health and operational effectiveness of the business. These metrics provide a foundation for informed decision-making and ensure alignment with the company's strategic objectives.

Financial KPIs considered by the board include revenue, gross profit, and EBITDA. These indicators highlight overall business performance, profitability, and cost efficiency.

KPI FY2024 (£) FY2023 (£) Movement (£) Movement (%)
Revenue 29,566,338 32,576,732 (3,010,394) -9.2%
Gross Profit 19,789,778 21,836,139 (2,046,361) -9.4%
EBITDA 1,084,978 4,617,949 (3,532,971) -76.5%

The decline across revenue, gross profit, and EBITDA reflects the impact of the delayed U.S. launch of the LYMA Laser PRO and the company's planned investment in team expansion, product development, and regulatory processes. While these factors adversely affected short-term profitability in 2024, they were undertaken to strengthen the company's platform for sustainable international growth from 2025 onwards .

ON BEHALF OF THE BOARD:





Mrs Lucy Sarah Goff - Director


29 September 2025

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

REPORT OF THE DIRECTORS
FOR THE YEAR ENDED 31 DECEMBER 2024

The directors present their report with the financial statements of the company for the year ended 31 December 2024.

DIVIDENDS
No dividends will be distributed for the year ended 31 December 2024.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 January 2024 to the date of this report.

Mrs Sarah Jane Crook
Mrs Lucy Sarah Goff
Mrs Sian Eleri Westerman
Mr Andrew Daniel Wolfson

RESEARCH AND DEVELOPMENT
Research and development remains central to the company's growth strategy. During the year, the company invested £695,154 (2023: £708,928) in R&D activities, focused primarily on new product development.

The company continues to claim R&D tax credits where eligible, and all R&D expenditure is carefully monitored to ensure alignment with strategic objectives and compliance with HMRC guidelines.

FUTURE DEVELOPMENTS
The company intends to continue investing in the development of new products to support future growth and meet evolving customer needs. Innovation remains a core part of our strategy, and ongoing work is focused on enhancing our existing product range and exploring new opportunities within our market.

In addition, the business will continue to progress its international growth plans, with a particular focus on strengthening its presence in key overseas markets. These efforts are expected to support long-term brand awareness and revenue diversification.

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

REPORT OF THE DIRECTORS
FOR THE YEAR ENDED 31 DECEMBER 2024


AUDITORS
The auditors, Fruition Advisory LLP, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:





Mrs Lucy Sarah Goff - Director


29 September 2025

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
LYMA LIFE LIMITED

Opinion
We have audited the financial statements of Lyma Life Limited (the 'company') for the year ended 31 December 2024 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity, Cash Flow Statement and Notes to the Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
LYMA LIFE LIMITED


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page three, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
LYMA LIFE LIMITED


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and noncompliance with laws and regulations, we considered the following:
- the nature of the industry and sector, control environment and business performance including the design of the Company remuneration policies, key drivers for directors’ remuneration, bonus levels and performance targets;
- results of our enquiries of management about their own identification and assessment of the risks of irregularities;
- any matters we identified having obtained and reviewed the Company documentation of their policies and procedures relating to:
- identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;
- detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
- the internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
- the matters discussed among the audit engagement team and involving relevant internal specialists, including tax specialists, regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in relation to revenue recognition. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.

We also obtained an understanding of the legal and regulatory frameworks that the Company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Companies Act and tax legislation.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the Company ability to operate or to avoid a material penalty. These included compliance with GDPR regulation.

Our procedures to respond to risks identified included the following:
- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- enquiring of management concerning actual and potential litigation and claims;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of
material misstatement due to fraud and reviewing internal reports;
- obtained an understanding of provisions and held discussions with management to understand the basis of
recognition or non-recognition of tax provisions; and
- in addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
LYMA LIFE LIMITED


We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members including internal specialists, and remained alert to any indications of fraud or noncompliance with laws and regulations throughout the audit.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Michelle Vincent (Senior Statutory Auditor)
for and on behalf of Fruition Advisory LLP
29 Wood Street
Stratford-upon-Avon
CV37 6JG

29 September 2025

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

INCOME STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024

2024 2023
Notes £    £   

TURNOVER 3 29,566,338 32,576,732

Cost of sales (9,776,560 ) (10,740,593 )
GROSS PROFIT 19,789,778 21,836,139

Administrative expenses (19,783,222 ) (18,364,553 )
OPERATING PROFIT 5 6,556 3,471,586


Interest payable and similar expenses 8 (11,002 ) (24,380 )
(LOSS)/PROFIT BEFORE TAXATION (4,446 ) 3,447,206

Tax on (loss)/profit 9 226,539 (558,797 )
PROFIT FOR THE FINANCIAL YEAR 222,093 2,888,409

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

OTHER COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024

2024 2023
Notes £    £   

PROFIT FOR THE YEAR 222,093 2,888,409


OTHER COMPREHENSIVE INCOME
Share based payment 63,414 63,241
Income tax relating to other
comprehensive income

-

-
OTHER COMPREHENSIVE INCOME
FOR THE YEAR, NET OF INCOME TAX

63,414

63,241
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

285,507

2,951,650

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

BALANCE SHEET
31 DECEMBER 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 10 403,008 173,192
Tangible assets 11 117,986 183,932
520,994 357,124

CURRENT ASSETS
Stocks 12 2,411,625 1,826,606
Debtors 13 3,186,284 3,981,873
Cash at bank 6,218,828 7,705,802
11,816,737 13,514,281
CREDITORS
Amounts falling due within one year 14 2,690,591 4,465,943
NET CURRENT ASSETS 9,126,146 9,048,338
TOTAL ASSETS LESS CURRENT
LIABILITIES

9,647,140

9,405,462

CREDITORS
Amounts falling due after more than one
year

15

(89,563

)

(99,658

)

PROVISIONS FOR LIABILITIES 18 - (33,734 )
NET ASSETS 9,557,577 9,272,070

CAPITAL AND RESERVES
Called up share capital 19 108 108
Share premium 20 2,000,486 2,000,486
Other reserves 20 133,585 70,171
Retained earnings 20 7,423,398 7,201,305
SHAREHOLDERS' FUNDS 9,557,577 9,272,070

The financial statements were approved by the Board of Directors and authorised for issue on 29 September 2025 and were signed on its behalf by:





Mrs Lucy Sarah Goff - Director


LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024

Called up
share Retained Share Other Total
capital earnings premium reserves equity
£    £    £    £    £   
Balance at 1 January 2023 108 4,312,896 2,000,486 6,930 6,320,420

Changes in equity
Total comprehensive income - 2,888,409 - 63,241 2,951,650
Balance at 31 December 2023 108 7,201,305 2,000,486 70,171 9,272,070

Changes in equity
Total comprehensive income - 222,093 - 63,414 285,507
Balance at 31 December 2024 108 7,423,398 2,000,486 133,585 9,557,577

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024

2024 2023
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 (567,496 ) 4,286,681
Interest paid (97 ) (13,475 )
Interest element of hire purchase
payments paid

(10,905

)

(10,905

)
Tax paid (619,645 ) (328,816 )
Net cash from operating activities (1,198,143 ) 3,933,485

Cash flows from investing activities
Purchase of intangible fixed assets (326,029 ) (85,782 )
Purchase of tangible fixed assets (21,232 ) (24,778 )
Sale of tangible fixed assets - 78,419
Net cash from investing activities (347,261 ) (32,141 )

Cash flows from financing activities
Loan repayments in year - (300,000 )
Capital repayments in year (10,095 ) (96,774 )
Amount introduced by directors 5,111 -
Amount withdrawn by directors - (280,269 )
Share based payment 63,414 63,241
Net cash from financing activities 58,430 (613,802 )

(Decrease)/increase in cash and cash equivalents (1,486,974 ) 3,287,542
Cash and cash equivalents at
beginning of year

2

7,705,802

4,418,260

Cash and cash equivalents at end of
year

2

6,218,828

7,705,802

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

NOTES TO THE CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024

1. RECONCILIATION OF (LOSS)/PROFIT BEFORE TAXATION TO CASH GENERATED FROM
OPERATIONS

2024 2023
£    £   
(Loss)/profit before taxation (4,446 ) 3,447,206
Depreciation charges 148,807 128,129
Loss/(profit) on disposal of fixed assets 34,584 (17,336 )
Finance costs 11,002 24,380
189,947 3,582,379
Increase in stocks (585,019 ) (325,458 )
Decrease/(increase) in trade and other debtors 983,274 (524,547 )
(Decrease)/increase in trade and other creditors (1,155,698 ) 1,554,307
Cash generated from operations (567,496 ) 4,286,681

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31 December 2024
31/12/24 1/1/24
£    £   
Cash and cash equivalents 6,218,828 7,705,802
Year ended 31 December 2023
31/12/23 1/1/23
£    £   
Cash and cash equivalents 7,705,802 4,418,260


3. ANALYSIS OF CHANGES IN NET FUNDS

At 1/1/24 Cash flow At 31/12/24
£    £    £   
Net cash
Cash at bank 7,705,802 (1,486,974 ) 6,218,828
7,705,802 (1,486,974 ) 6,218,828
Debt
Finance leases (110,274 ) 10,095 (100,179 )
(110,274 ) 10,095 (100,179 )
Total 7,595,528 (1,476,879 ) 6,118,649

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1. STATUTORY INFORMATION

Lyma Life Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Significant judgements and estimates
Research and development provisions
Provision has been made in the financial statements for the total claim expected to be received relating
to research and development expenditure during the year.

Fixed asset depreciationand amortisation
Fixed assets are depreciated over their useful economic lives to an estimated residual value. Residual
values are calculated using the best estimate of our assets value at the end of its useful life.

Stock valuation
Stock is valued at the lower of cost price or sales price. This is in line with the accounting policy within stock. A provision within the accounts has been made to stock of which relates to it being obsolete or that of expired items or due to expire before it can all be sold.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible
assets are measured at cost less accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life
cannot be made, the useful life shall not exceed ten years.

The estimated useful lives range as follows:

Trademarks and patents - 5 years straight line
Computer software - 5 years straight line

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Leasehold property - 5 years straight line
Motor vehicles - 3 years straight line
Fixture & fittings - 5 years straight line
Office equipment - 3 years straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in Statement of Income and Retained Earnings.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first in, fist-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit and loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

2. ACCOUNTING POLICIES - continued

Hire purchase and leasing commitments
Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Trade debtors
Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business

Trade debtors are recognised at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provison for impairment. A provison for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Cash and Cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade Creditors
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period. If there is an unconditional right to defer settlement for at least twelve months after the reporting period, they are presented as non-current liabilities.

Trade creditors are recgonised initially at the transaction price and subsequently measured at amortised cost using the effecting interest method.

Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources or receivables, net of the direct cost of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

3. TURNOVER

The turnover and loss (2023 - profit) before taxation are attributable to the one principal activity of the company.

An analysis of turnover by geographical market is given below:

2024 2023
£    £   
United Kingdom 8,617,556 8,764,211
Europe 3,743,094 3,366,447
United States of America 12,323,105 18,611,286
Rest of world 4,882,583 1,834,788
29,566,338 32,576,732

4. EMPLOYEES AND DIRECTORS
2024 2023
£    £   
Wages and salaries 5,700,360 4,633,806
Social security costs 570,853 459,732
Other pension costs 148,532 54,173
6,419,745 5,147,711

The average number of employees during the year was as follows:
2024 2023

Operations 43 36
Directors 1 2
44 38

2024 2023
£    £   
Directors' remuneration 537,379 732,000
Directors' pension contributions to money purchase schemes 1,321 1,321

The number of directors to whom retirement benefits were accruing was as follows:

Money purchase schemes 1 1

Information regarding the highest paid director is as follows:
2024 2023
£    £   
Emoluments etc 537,379 459,500
Pension contributions to money purchase schemes 1,321 1,321

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

5. OPERATING PROFIT

The operating profit is stated after charging/(crediting):

2024 2023
£    £   
Recruitment fees 278,435 227,853
Other operating costs 240,182 55,857
Depreciation - owned assets 45,342 41,699
Depreciation - assets on hire purchase contracts 41,836 41,836
Loss/(profit) on disposal of fixed assets 34,584 (17,336 )
Patents and licences amortisation 37,677 35,618
Computer software amortisation 23,952 8,976
Foreign exchange differences 166,704 22,794

6. AUDITORS' REMUNERATION
2024 2023
£    £   
Fees payable to the company's auditors for the audit of the
company's financial statements

20,000

15,000

7. EXCEPTIONAL ITEMS
2024 2023
£    £   
Exceptional items (347,382 ) (404,003 )

The costs within exceptional items relate to legal charges including prior payout disputes and dismissal of key management personal.

8. INTEREST PAYABLE AND SIMILAR EXPENSES
2024 2023
£    £   
Other interest payable 97 13,475
Hire purchase 10,905 10,905
11,002 24,380

9. TAXATION

Analysis of the tax (credit)/charge
The tax (credit)/charge on the loss for the year was as follows:
2024 2023
£    £   
Current tax:
UK corporation tax - 525,063
Over/under for prior year (73,079 ) -
Total current tax (73,079 ) 525,063

Deferred tax (153,460 ) 33,734
Tax on (loss)/profit (226,539 ) 558,797

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

9. TAXATION - continued

Reconciliation of total tax (credit)/charge included in profit and loss
The tax assessed for the year is lower than the standard rate of corporation tax in the UK. The difference is explained below:

2024 2023
£    £   
(Loss)/profit before tax (4,446 ) 3,447,206
(Loss)/profit multiplied by the standard rate of corporation tax in the
UK of 25% (2023 - 25%)

(1,112

)

861,802

Effects of:
Expenses not deductible for tax purposes 9,999 13,399
Depreciation in excess of capital allowances 19,590 24,783
Adjustments to tax charge in respect of previous periods (73,079 ) -
Patent box deduction (32,479 ) (308,160 )
R&D relief (149,458 ) -
Tax rate change - (33,027 )
Total tax (credit)/charge (226,539 ) 558,797

Tax effects relating to effects of other comprehensive income

2024
Gross Tax Net
£    £    £   
Share based payment 63,414 - 63,414

2023
Gross Tax Net
£    £    £   
Share based payment 63,241 - 63,241

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

10. INTANGIBLE FIXED ASSETS
Patents
and Computer
licences software Totals
£    £    £   
COST
At 1 January 2024 178,724 55,440 234,164
Additions 57,962 268,067 326,029
Disposals - (55,440 ) (55,440 )
At 31 December 2024 236,686 268,067 504,753
AMORTISATION
At 1 January 2024 51,204 9,768 60,972
Amortisation for year 37,677 23,952 61,629
Eliminated on disposal - (20,856 ) (20,856 )
At 31 December 2024 88,881 12,864 101,745
NET BOOK VALUE
At 31 December 2024 147,805 255,203 403,008
At 31 December 2023 127,520 45,672 173,192

11. TANGIBLE FIXED ASSETS
Fixtures
Short and Motor Computer
leasehold fittings vehicles equipment Totals
£    £    £    £    £   
COST
At 1 January 2024 83,648 36,789 125,508 83,892 329,837
Additions - - - 21,232 21,232
At 31 December 2024 83,648 36,789 125,508 105,124 351,069
DEPRECIATION
At 1 January 2024 34,654 15,013 41,836 54,402 145,905
Charge for year 16,729 7,358 41,836 21,255 87,178
At 31 December 2024 51,383 22,371 83,672 75,657 233,083
NET BOOK VALUE
At 31 December 2024 32,265 14,418 41,836 29,467 117,986
At 31 December 2023 48,994 21,776 83,672 29,490 183,932

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

11. TANGIBLE FIXED ASSETS - continued

Fixed assets, included in the above, which are held under hire purchase contracts are as follows:
Motor
vehicles
£   
COST
At 1 January 2024
and 31 December 2024 125,508
DEPRECIATION
At 1 January 2024 41,836
Charge for year 41,836
At 31 December 2024 83,672
NET BOOK VALUE
At 31 December 2024 41,836
At 31 December 2023 83,672

12. STOCKS
2024 2023
£    £   
Stocks 2,411,625 1,826,606

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 691,100 701,360
Other debtors 1,572,241 1,911,244
Directors' loan accounts 275,158 280,269
Tax 167,661 94,591
Deferred tax asset 119,726 -
Prepayments and accrued income 360,398 994,409
3,186,284 3,981,873

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Hire purchase contracts (see note 16) 10,616 10,616
Trade creditors 1,099,809 1,737,737
Tax - 619,654
Social security and other taxes 352,601 244,758
VAT 651,414 826,291
Other creditors 94,750 17,268
Accruals and deferred income 481,401 1,009,619
2,690,591 4,465,943

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

15. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2024 2023
£    £   
Hire purchase contracts (see note 16) 89,563 99,658

16. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Hire purchase contracts
2024 2023
£    £   
Net obligations repayable:
Within one year 10,616 10,616
Between one and five years 89,563 99,658
100,179 110,274

Non-cancellable operating leases
2024 2023
£    £   
Within one year 225,375 201,775
Between one and five years 85,388 256,163
310,763 457,938

17. SECURED DEBTS

The following secured debts are included within creditors:

2024 2023
£    £   
Hire purchase contracts 100,179 110,274

18. PROVISIONS FOR LIABILITIES
2023
£   
Deferred tax 33,734

Deferred
tax
£   
Balance at 1 January 2024 33,734
Provided during year (153,460 )
Balance at 31 December 2024 (119,726 )

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

19. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
6,967 Ordinary A 0.01 70 70
3,106 Ordinary B 0.01 31 31
694 Ordinary C 0.01 7 7
108 108

20. RESERVES
Retained Share Other
earnings premium reserves Totals
£    £    £    £   

At 1 January 2024 7,201,305 2,000,486 70,171 9,271,962
Profit for the year 222,093 222,093
Share based payment - - 63,414 63,414
At 31 December 2024 7,423,398 2,000,486 133,585 9,557,469

21. PENSION COMMITMENTS

The company operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the company to the scheme and amount to £148,531 (2023: £54,173). Contributions totalling £72,837 (2023: -£257 ) were payable to the scheme at the end of the year and are included in creditors.

22. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31 December 2024 and 31 December 2023:

2024 2023
£    £   
Mrs Lucy Sarah Goff
Balance outstanding at start of year 280,269 -
Amounts advanced - 280,269
Amounts repaid (5,111 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 275,158 280,269

LYMA LIFE LIMITED (REGISTERED NUMBER: 10613047)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

23. SHARE-BASED PAYMENT TRANSACTIONS

The company operates share-based remuneration scheme for certain employees.

Options are exercisable at a price equal to the estimated fair value of the shares on the date of the grant. The options are granted under the scheme and are exercisable if there are certain exit events. If the options remain unexercised after a period of ten years from the date of grant, the option expire. The only other vesting condition is that the employees remain in employment through the vesting period.

Details of the share options outstanding during the year are as follows:

31 Dec 202431 Dec 2024



Weighted
average
exercise
price (pence



)



Number
Outstanding at the beginning of the year750.00216
Granted during the year--
Expired during the year--
Outstanding at the end of the year750.00216

None of the options expired during the year. 72 of the 216 options outstanding at the end of the year had vested but were not exercisable at the year end.

The total expense recognised in the profit and loss in the year is £63,414 (2023: 63,241).The total carrying amount at the balance sheet date included in other reserves is £133,585 (2023: 70,171).